These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 35169975

  • 1. ASO Author Reflections: Preoperative Denosumab May Increase the Risk of Local Recurrence of Giant Cell Tumor of Bone after Curettage Surgery.
    Asano N, Horiuchi K.
    Ann Surg Oncol; 2022 Jun; 29(6):4001. PubMed ID: 35169975
    [No Abstract] [Full Text] [Related]

  • 2. Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.
    Tsukamoto S, Tanaka Y, Mavrogenis AF, Kido A, Kawaguchi M, Errani C.
    Clin Orthop Relat Res; 2020 May; 478(5):1076-1085. PubMed ID: 31794487
    [Abstract] [Full Text] [Related]

  • 3. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
    Müller DA, Beltrami G, Scoccianti G, Campanacci DA, Franchi A, Capanna R.
    World J Surg Oncol; 2016 Nov 04; 14(1):281. PubMed ID: 27809843
    [Abstract] [Full Text] [Related]

  • 4. Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery.
    Asano N, Saito M, Kobayashi E, Morii T, Kikuta K, Watanabe I, Anazawa U, Takeuchi K, Suzuki Y, Susa M, Nishimoto K, Ishii R, Miyazaki N, Mrioka H, Kawai A, Horiuchi K, Nakayama R.
    Ann Surg Oncol; 2022 Jun 04; 29(6):3992-4000. PubMed ID: 35175454
    [Abstract] [Full Text] [Related]

  • 5. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
    Errani C, Tsukamoto S, Leone G, Righi A, Akahane M, Tanaka Y, Donati DM.
    J Bone Joint Surg Am; 2018 Mar 21; 100(6):496-504. PubMed ID: 29557866
    [Abstract] [Full Text] [Related]

  • 6. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
    Zhang RZ, Ma TX, Qi DW, Zhao M, Hu T, Zhang GC.
    Orthop Surg; 2019 Dec 21; 11(6):1101-1108. PubMed ID: 31762217
    [Abstract] [Full Text] [Related]

  • 7. Denosumab for Bone Giant Cell Tumor of the Distal Radius.
    Tsukamoto S, Mavrogenis AF, Tanzi P, Leone G, Ciani G, Righi A, Akahane M, Honoki K, Tanaka Y, Donati DM, Errani C.
    Orthopedics; 2020 Sep 01; 43(5):284-291. PubMed ID: 32745221
    [Abstract] [Full Text] [Related]

  • 8. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
    Perrin DL, Visgauss JD, Wilson DA, Griffin AM, Abdul Razak AR, Ferguson PC, Wunder JS.
    Bone Joint J; 2021 Jan 01; 103-B(1):184-191. PubMed ID: 33380180
    [Abstract] [Full Text] [Related]

  • 9. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K, Suehara Y, Okubo T, Sasa K, Kurihara T, Akaike K, Kubota D, Torigoe T, Hasegawa N, Ishii M, Nakamura Y, Kim Y, Takagi T, Kaneko K, Hayashi T, Saito T.
    J Orthop Surg (Hong Kong); 2020 Jan 01; 28(2):2309499020929786. PubMed ID: 32539628
    [Abstract] [Full Text] [Related]

  • 10. Combined preoperative denosumab and adjuvant microwave ablation for high-risk giant cell tumor of bone: a retrospective study in a single center.
    Zheng C, Xu G, Zhou X, Qiu J, Lan T, Zhang S, Li W.
    J Orthop Surg Res; 2024 Aug 17; 19(1):488. PubMed ID: 39154187
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Association between preoperative denosumab and the risk of local recurrence in patients with giant cell tumor of bone: A meta-analysis and systematic review.
    Sun Z, Wu Z, Zhang L, Jia Q, Zhou Z, Xiao J.
    J Cancer Res Ther; 2023 Feb 17; 19(1):25-33. PubMed ID: 37006039
    [Abstract] [Full Text] [Related]

  • 13. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation.
    Tsukamoto S, Hindiskere S, Honoki K, Mavrogenis AF, Tanaka Y, Chinder PS, Donati DM, Errani C.
    Int Orthop; 2023 Jan 17; 47(1):265-273. PubMed ID: 36282294
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study.
    Urakawa H, Yonemoto T, Matsumoto S, Takagi T, Asanuma K, Watanuki M, Takemoto A, Naka N, Matsumoto Y, Kawai A, Kunisada T, Kubo T, Emori M, Hiraga H, Hatano H, Tsukushi S, Nishida Y, Akisue T, Morii T, Takahashi M, Nagano A, Yoshikawa H, Sato K, Kawano M, Hiraoka K, Tanaka K, Iwamoto Y, Ozaki T.
    World J Surg Oncol; 2018 Aug 08; 16(1):160. PubMed ID: 30089488
    [Abstract] [Full Text] [Related]

  • 17. A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610.
    Urakawa H, Mizusawa J, Tanaka K, Eba J, Hiraga H, Kawai A, Nishida Y, Hosaka M, Iwamoto Y, Fukuda H, Ozaki T.
    Jpn J Clin Oncol; 2019 Apr 01; 49(4):379-382. PubMed ID: 30796832
    [Abstract] [Full Text] [Related]

  • 18. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis.
    Reddy K, Ramirez L, Kukreja K, Venkatramani R.
    J Pediatr Hematol Oncol; 2021 Mar 01; 43(2):e215-e218. PubMed ID: 31714440
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
    Traub F, Singh J, Dickson BC, Leung S, Mohankumar R, Blackstein ME, Razak AR, Griffin AM, Ferguson PC, Wunder JS.
    Eur J Cancer; 2016 May 01; 59():1-12. PubMed ID: 26990281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.